ArticleMolecular and clinical oncology2026
Prognostic impact of HLA class I immunohistochemistry staining intensity with regard to the risk of recurrence of adenoid cystic carcinoma.
Article in Molecular and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenoid cystic carcinoma (AdCC) evolves from the salivary glands and may arise in the head and neck region or outside of this area. The symptoms of AdCC are generally nonspecific, and its diagnosis is challenging due to its heterogeneous histopathology and indolent growth. Moreover, reliable prognostic markers are lacking. Therefore, the present study investigated the prognostic potential of immunohistochemical staining of the immune markers HLA class I, CD4, CD8 and FOXP3 in AdCC. In total, 72 patients diagnosed with AdCC between January 2000, and December 2014 were included. Biopsy material underwent immunohistochemical staining for the aforementioned markers, and staining extent and intensity in the tumour and corresponding stroma were assessed, and their association with clinical outcome was investigated. Patients with analogous staining intensity of HLA class I in the tumour tissue to that in the stromal tissue had significantly fewer recurrences, as compared with those with lower HLA class I intensity staining in the tumour than in the stroma. By contrast, CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.